Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.

ABSTRACT:

Introduction

Radium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study, we aimed to ambispectively analyze overall survival (OS) and prognostic features in mCRPC in patients receiving Ra-223 as per clinical routine practice and identify the most suitable treatment sequence.

Patients and methods

This study is observational, multicentric, and ambispective. Eligibility criteria included mCRPC patients treated with Ra-223, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, without visceral metastases, and no more than three cm i

SUBMITTER: Anido-Herranz U 

PROVIDER: S-EPMC11106362 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature